Daptomycin Research Dosage: Published Protocol Reference
Daptomycin dosage references vary by route and study context. The database lists Intravenous: 4 mg/kg, Once daily, Intravenous: 6 mg/kg, Once daily, and Intravenous: 8-12 mg/kg, Once daily. These are research-context references, not a universal protocol.
Direct Answer
Daptomycin (Cubicin) is FDA-approved for serious gram-positive infections including MRSA bacteremia, endocarditis, and complicated skin infections. It is a first-line IV antibiotic with extensive Phase 3 data and a 20+ year clinical track record. For researchers studying gram-positive infection treatment, daptomycin is a validated standard-of-care option with high-quality evidence.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Immune Support
- Best for
- MRSA bacteremia, right-sided endocarditis, complicated skin and soft tissue infections, gram-positive infection treatment
Research Dosage References
- <strong>Intravenous</strong> - 4 mg/kg - Once daily - FDA-approved dose for complicated skin and skin structure infections. Infused over 30 minutes or as 2-minute IV push.
- <strong>Intravenous</strong> - 6 mg/kg - Once daily - FDA-approved dose for S. aureus bacteremia and right-sided endocarditis. Higher doses (8-12 mg/kg) used off-label for refractory infections.
- <strong>Intravenous</strong> - 8-12 mg/kg - Once daily - Off-label high-dose regimen for difficult-to-treat infections. Requires close CPK monitoring.
Half-Life
~8-9 hours (supports once-daily dosing; prolonged in renal impairment).
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Daptomycin, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Do NOT use for pneumonia (inactivated by pulmonary surfactant)
- Monitor CPK weekly during therapy
- Dose adjustment required in renal impairment (CrCl <30 mL/min)
- Not effective against gram-negative organisms
- Consider discontinuing statins during therapy to reduce myopathy risk
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | MRSA Bacteremia Treatment (Level A), Complicated Skin Infections (Level A), and CPK Elevation (Adverse) (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Daptomycin Research Dosage: Published Protocol Reference." Last reviewed 2026-04-04. https://examinepeptides.com/answers/daptomycin-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.